Drug intelligence / Profile preview

aluminium phosphate

Development stage: Unknown
Lead developer: Pharmatis
Modality: Small Molecules
Administration: Oral

Overview

Aluminium phosphate is an antacid and gastric mucosal protective agent used to manage symptoms of gastric acidity and mucosal irritation. It works by neutralizing gastric hydrochloric acid and forming a protective, colloidal film over the gastric and esophageal mucosa, which shields the lining from further damage and promotes healing. In China, a specific formulation known as ALUPHO (Aluminium Phosphate Oral Suspension) is being developed by Pharmatis and Yikang (Guangzhou) Consulting Service. It is currently in Phase 3 clinical trials (e.g., CTR20253554) evaluating its efficacy and safety in relieving epigastric pain associated with chronic gastritis.

Brand names: Phosphalugel
Other names: Aluminium Phosphate Oral Suspension

Beyond the preview

Go deeper on aluminium phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aluminium phosphate.

Explore the full profile